With the population of immunocompromised individuals growing drastically over the past few decades due to the continuing AIDS pandemic and advances in medical technologies such as organ transplantation and chemotherapy, there is an increasing prevalence of opportunistic fungal infections. One major fungal pathogen involved in such infections is Cryptococcus neoformans that is found worldwide. Approximately a quarter million people are infected with this deadly fungus annually with an estimated 180,000 deaths, where the majority of infected individuals succumb to severe disease. Despite this substantial burden of disease, treatment options for C. neoformans are limited as current drugs are associated with high toxicity, cost, drug resistance, and drug cross reactivity. Thus, there is an urgent need to identify new antifungal targets. This fungus is predominantly found in purine-rich bird guano and yet commonly infects the purine-poor central nervous system. The stark contrast in purine availability between C. neoformans environmental niche and preferred infection site highlights the importance of de novo purine biosynthesis during infection. Therefore, the enzymes of the purine biosynthesis pathway could be promising as antifungal targets.Purine biosynthesis is a crucial metabolic pathway for all living organisms as purines are an essential component of DNA and are involved in many cellular processes. The first purine base, consisting of an imidazole and a pyrimidine ring, is synthesised via eleven enzymatic reactions. In the first chapter, I investigated the genes encoding purine biosynthesis enzymes in various species across the domains of life. These genes have gone through multiple fusion events that have resulted in the creation of multifunctional enzymes that perform multiple steps in the de novo purine biosynthesis pathway. Bioinformatic analyses were conducted to identify genes encoding purine biosynthesis enzymes through the genomes for 203 species, where key differences in the purine biosynthesis enzymes between humans and several pathogens including C. neoformans revealed promising drug targets.In previous studies investigating purine metabolism in C. neoformans, the deletion of enzymes from the later portion of the pathway in the fungal pathogen led to their inability to cause infection in mice. However, no studies have been conducted in C. neoformans to investigate the initial portion of the pathway before synthesis of the first imidazole ring. In the second and third chapter, genetic and protein oligomeric characterisation were conducted for PRPP amidotransferase and FGAM synthetase, the first and fourth enzyme of the pathway respectively. In the fourth chapter, the bifunctional GAR synthetase/AIR synthetase, responsible for the second and fifth steps of the pathway, was genetically, biochemically and structurally characterised. The genes encoding these enzymes were deleted from the C. neoformans genome, and FGAM synthetase was shown to be necessary for virulence trait production while PRPP amidotransferase and bifunctional GAR synthetase/AIR synthetase were essential for C. neoformans infection in mice. These enzymes were recombinantly expressed and their oligomeric states were determined. GAR synthetase and AIR synthetase protein were further characterised to uncover differences in GAR synthetase activity compared to the metazoan enzymes. In addition, amino acid differences in the binding sites of GAR synthetase and differences in AIR synthetase dimer interfaces compared to the human enzyme were identified which may be exploited for antifungal drug design.Bioinformatic analyses from the first chapter showed that many purine biosynthesis genes were fused to encode for multifunctional proteins, clearly indicating a preference for proximity. The formation of a higher order complex known as the purinosome was first observed in human HELA cell lines by fluorescently tagging the de novo purine biosynthesis enzymes. Purinosome assembly is a dynamic and transient process where these enzymes cluster together during purine depletion and disassociates in purine-rich environments. Purinosome formation has yet to be demonstrated in C. neoformans. Before we can proceed with fluorescently tagging purine enzymes, we needed to expand the current toolkit of fluorescent proteins in C. neoformans. In the fifth chapter, we created and characterised a library of codon optimised a wide range of fluorescent proteins that were not previously available in C. neoformans. The availability of these fluorescence proteins led to the initial strategy for fluorescently tagging the de novo purine enzymes at their native locus, however this method of fluorescent tagging requires optimisation due to low fluorescence observed. Overall, my thesis summarises the potential for de novo purine biosynthesis enzymes as antifungals for treatment of disseminated fungal infections. Finally, by characterising a wider range of fluorescent proteins, a highly modular tool can now be utilised for the future investigations in C. neoformans.